The storied success of copyright’s flagship drug has undeniably shaped the pharmaceutical landscape. However, investing in companies heavily dependent on copycat drugs and the declining patent protection https://friendlybookmark.com/story21264116/the-blue-pill-and-pharmaceutical-companies-a-risky-opportunity